JPS6318567B2 - - Google Patents
Info
- Publication number
- JPS6318567B2 JPS6318567B2 JP3020979A JP3020979A JPS6318567B2 JP S6318567 B2 JPS6318567 B2 JP S6318567B2 JP 3020979 A JP3020979 A JP 3020979A JP 3020979 A JP3020979 A JP 3020979A JP S6318567 B2 JPS6318567 B2 JP S6318567B2
- Authority
- JP
- Japan
- Prior art keywords
- boronophenylalanine
- present
- boron
- compound
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 6
- 229910052796 boron Inorganic materials 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- OPXXRPCTZACPLL-QMMMGPOBSA-N (2s)-2-(boronoamino)-3-phenylpropanoic acid Chemical class OB(O)N[C@H](C(O)=O)CC1=CC=CC=C1 OPXXRPCTZACPLL-QMMMGPOBSA-N 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- NFIVJOSXJDORSP-QMMMGPOBSA-N (2s)-2-amino-3-(4-boronophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(B(O)O)C=C1 NFIVJOSXJDORSP-QMMMGPOBSA-N 0.000 description 12
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 6
- 150000001639 boron compounds Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KMMFNUQTSFZRLZ-JTQLQIEISA-N (2S)-2-acetamido-3-(4-boronophenyl)propanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(B(O)O)C=C1 KMMFNUQTSFZRLZ-JTQLQIEISA-N 0.000 description 2
- ITAYDCRFNXQNBL-QRPNPIFTSA-N (2s)-2-amino-3-(4-boronophenyl)propanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CC=C(B(O)O)C=C1 ITAYDCRFNXQNBL-QRPNPIFTSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- -1 N-acetyl-O-boronophenylalanine Chemical compound 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 150000001638 boron Chemical class 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical group C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Radiation-Therapy Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3020979A JPS55122720A (en) | 1979-03-15 | 1979-03-15 | Adjuvant for neutron capture therapy for skin cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3020979A JPS55122720A (en) | 1979-03-15 | 1979-03-15 | Adjuvant for neutron capture therapy for skin cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS55122720A JPS55122720A (en) | 1980-09-20 |
| JPS6318567B2 true JPS6318567B2 (it) | 1988-04-19 |
Family
ID=12297332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3020979A Granted JPS55122720A (en) | 1979-03-15 | 1979-03-15 | Adjuvant for neutron capture therapy for skin cancer |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS55122720A (it) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0229946U (it) * | 1988-08-10 | 1990-02-26 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4516535A (en) * | 1982-06-22 | 1985-05-14 | Nuclear Medicine, Inc. | Methods for neutron-capture tumor therapy |
| US5935944A (en) * | 1993-09-10 | 1999-08-10 | Neutron Technology Corporation | Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA) |
| US5492900A (en) * | 1993-09-10 | 1996-02-20 | Neutron Technology Corporation | Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA) |
| JP2006096870A (ja) * | 2004-09-29 | 2006-04-13 | Stella Chemifa Corp | ホウ素含有化合物 |
-
1979
- 1979-03-15 JP JP3020979A patent/JPS55122720A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0229946U (it) * | 1988-08-10 | 1990-02-26 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS55122720A (en) | 1980-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4247110B2 (ja) | 新規メタロポルフィリン及び放射線治療用放射線増感剤としてのそれらの使用 | |
| EP3424561B1 (en) | Boron neutron capture treating system and alpha-amino acid-like boron trifluoride compounds for use in treating tumors | |
| Denekamp et al. | Further investigations of the response of irradiated mouse skin | |
| CN107224675B (zh) | 硼中子捕获治疗系统 | |
| Hatanaka et al. | The present status of boron-neutron capture therapy for tumors | |
| US4913907A (en) | Porphycene anti-cancer agents and treatment methods | |
| JPS6318567B2 (it) | ||
| Schaffer et al. | Photofrin II as an efficient radiosensitizing agent in an experimental tumor | |
| Adams et al. | Biological basis of radiosensitization by hypoxic-cell radiosensitizers | |
| Chaplin | Postirradiation modification of tumor blood flow: a method to increase the effectiveness of chemical radiosensitizers | |
| Hlavka et al. | Radioactive 7-iodo-6-deoxytetracycline in tumour tissue | |
| WO2000001413A1 (en) | Intracellular sensitizers for sonodynamic therapy | |
| Slatkin et al. | Distributions of sulfhydryl borane monomer and dimer in rodents and monomer in humans: boron neutron capture therapy of melanoma and glioma in boronated rodents | |
| Laverick et al. | Potentiation of the radiation response of hypoxic mammalian cells by cis-dichlorobis (isopropylamine) trans-dihydroxy platinum IV (CHIP) | |
| Goodman et al. | Ultrastructural microvascular response to boron neutron capture therapy in an experimental model | |
| TAKEUCHI et al. | Electron microscopic study on the response of the normal canine brain to boron-neutron capture therapy | |
| Morris et al. | Boron neutron capture therapy of the rat 9L gliosarcoma: evaluation of the effects of shark cartilage. | |
| US20010051760A1 (en) | Use of photofrin as a radiosensitizer | |
| Chan et al. | In vitro effects of irradiation combined with actinomycin D | |
| Kim | Combined hyperthermia and radiation therapy in cancer treatment: Current status | |
| EP0730870A1 (en) | Radioactive chitosan complex and its macroaggregates for use in internal radiation therapy and their preparation method | |
| TAKAGAKI et al. | Gadolinium neutron capture therapy for malignant brain tumors | |
| Schneyer et al. | Modification of irradiation effects on rat parotid by chronic pretreatment with isoproterenol | |
| Yamada et al. | Thermochemotherapy for malignant melanoma: overcoming heterogeneity in drug sensitivity | |
| COLE et al. | The radioprotective and anti-tumor effect of mixed bacterial toxins and anthramycin |